SNPX - התחייבויות לטווח ארוך להון synaptogen.com

Synaptogenix, Inc. (SNPX) is a micro-cap biotech company that is not yet profitable and is competing for resources in isolation from industry behemoths. The business relies on the development of a dementia treatment that promotes the restoration of neural connections. The available price action vector on GURU.Markets is recorded at 0.00. Exclusive therapy rights and lobbyist support protect the project despite strict FDA oversight.

The indicator is calculated as the ratio of long-term liabilities to equity. This metric determines the degree of financial leverage by assessing the company's reliance on borrowed funds for long-term planning. For Synaptogenix, Inc. (SNPX), this is critical when financing the development of Bryostatin-1 through scientific partnerships. By analyzing the history of financial leverage regarding long-term debt, an investor can identify risks of excessive debt load or asset overvaluation.